Stock QLGN QUALIGEN THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Qualigen Therapeutics, Inc.

Equities

QLGN

US74754R2022

Biotechnology & Medical Research

Real-time Estimate Cboe BZX
Other stock markets
 12:19:58 2024-06-27 EDT 		5-day change 1st Jan Change
0.18 USD +7.72% Intraday chart for Qualigen Therapeutics, Inc. +4.18% -66.45%
04-16 Marizyme Enters into Co-Development Agreement with Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft? CI
04-08 Qualigen Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2020 2021 2022 2023
Capitalization 1 80.39 37.76 5.428 2.85
Enterprise Value (EV) 1 57.04 21.9 0.9467 3.747
P/E ratio -2.01 x -1.75 x -0.27 x -0.21 x
Yield - - - -
Capitalization / Revenue 21.2 x 6.68 x 1.09 x -
EV / Revenue 15 x 3.87 x 0.19 x -
EV / EBITDA -4.58 x -1.29 x -0.05 x -0.33 x
EV / FCF 101,400,113 x -2,347,920 x -281,511 x -878,213 x
FCF Yield 0% -0% -0% -0%
Price to Book 4.49 x 2.28 x 0.75 x -1.4 x
Nbr of stocks (in thousands) 2,671 3,529 4,211 5,181
Reference price 2 30.10 10.70 1.289 0.5500
Announcement Date 21-03-31 22-03-31 23-05-02 24-04-08
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 9.776 5.803 3.799 5.654 4.984 -
EBITDA 1 0.2625 -0.7179 -12.44 -16.95 -17.79 -11.3
EBIT 1 -0.2026 -1.055 -12.56 -17.06 -17.94 -11.3
Operating Margin -2.07% -18.18% -330.57% -301.8% -360.03% -
Earnings before Tax (EBT) 1 -0.3514 -1.196 -26.06 -17.89 -21.3 -12.48
Net income 1 -0.3564 -1.2 -26.06 -17.9 -18.64 -13.42
Net margin -3.65% -20.69% -685.94% -316.55% -374.04% -
EPS 2 -0.6363 -2.143 -14.95 -6.101 -4.854 -2.646
Free Cash Flow - -0.6467 0.5625 -9.326 -3.363 -4.267
FCF margin - -11.14% 14.81% -164.95% -67.48% -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 20-02-04 20-02-04 21-03-31 22-03-31 23-05-02 24-04-08
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4
Net sales 1 1.155 1.481 0.722 1.431 1.441 1.39 1.607 1.627 0.4269 -
EBITDA - - - - - - - - - -
EBIT 1 -4.808 -4.647 -5.009 -4.141 -4.383 -4.409 -3.693 -3.551 -2.778 -2.274
Operating Margin -416.24% -313.76% -693.69% -289.5% -304.15% -317.25% -229.77% -218.26% -650.79% -
Earnings before Tax (EBT) 1 -2.858 -6.057 -4.319 -4.122 -4.056 -8.803 -4.271 -3.546 -3.235 -2.472
Net income 1 -2.859 -6.061 -4.32 -4.123 -3.825 -6.372 -3.846 -3.464 -3.657 -2.45
Net margin -247.48% -409.17% -598.28% -288.24% -265.44% -458.46% -239.32% -212.92% -856.49% -
EPS 2 -1.000 -2.000 -1.200 -1.100 -1.000 -1.550 -0.7800 -0.6900 -0.7200 -0.4700
Dividend per Share - - - - - - - - - -
Announcement Date 21-11-15 22-03-31 22-05-13 22-08-15 22-11-14 23-05-02 23-05-15 23-08-14 23-11-14 24-04-08
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 0.65 1.91 - - - 0.9
Net Cash position 1 - - 23.3 15.9 4.48 -
Leverage (Debt/EBITDA) 2.474 x -2.658 x - - - -0.0794 x
Free Cash Flow - -0.65 0.56 -9.33 -3.36 -4.27
ROE (net income / shareholders' equity) - -275% 172% -103% -166% -374%
ROA (Net income/ Total Assets) - -16.1% -24.5% -41% -53.5% -66.9%
Assets 1 - 7.435 106.6 43.6 34.84 20.05
Book Value Per Share 2 1.540 -0.5400 6.700 4.690 1.720 -0.3900
Cash Flow per Share 2 0.1100 0.2200 8.780 4.970 1.670 0.0700
Capex 1 0.41 0.02 0.28 0.13 0.32 -
Capex / Sales 4.15% 0.38% 7.32% 2.38% 6.4% -
Announcement Date 20-02-04 20-02-04 21-03-31 22-03-31 23-05-02 24-04-08
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
QUALIGEN THERAPEUTICS, INC. Stock Qualigen Therapeutics, Inc.
-66.45% 1.05M
MODERNA, INC. Stock Moderna, Inc.
+21.87% 46.93B
LONZA GROUP AG Stock Lonza Group AG
+37.63% 39.08B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-8.28% 38.48B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
+31.29% 31.01B
CELLTRION, INC. Stock Celltrion, Inc.
-13.75% 26.14B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+11.29% 25.88B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+35.88% 12.53B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-6.42% 11.36B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-12.42% 10.65B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. QLGN Stock
  4. Financials Qualigen Therapeutics, Inc.